Orphazyme AS (CHIX:ORPHAC) EBITDA Margin % : 0.00% (As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Orphazyme AS's EBITDA for the six months ended in Jun. 2022 was kr-27.24 Mil. Orphazyme AS's Revenue for the six months ended in Jun. 2022 was kr0.00 Mil. Therefore, Orphazyme AS's EBITDA margin for the quarter that ended in Jun. 2022 was 0.00%.

Orphazyme AS EBITDA Margin % Historical Data

The historical data trend for Orphazyme AS's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS EBITDA Margin % Chart

Orphazyme AS Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EBITDA Margin %

Get a 7-Day Free Trial

-1,668.59

Orphazyme AS Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
EBITDA Margin %	Get a 7-Day Free Trial									-	-	-	-1,560.25	-

Competitive Comparison of Orphazyme AS's EBITDA Margin %

For the Biotechnology subindustry, Orphazyme AS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orphazyme AS's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orphazyme AS's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Orphazyme AS's EBITDA Margin % falls into.

Orphazyme AS EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Orphazyme AS's EBITDA Margin % for the fiscal year that ended in Dec. 2021 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2021 )	/	Revenue (A: Dec. 2021 )
	=	-603.911	/	36.193
	=	-1,668.59 %

Orphazyme AS's EBITDA Margin % for the quarter that ended in Jun. 2022 is calculated as

EBITDA Margin %	=	EBITDA (Q: Jun. 2022 )	/	Revenue (Q: Jun. 2022 )
	=	-27.239	/	0
	=	%

Orphazyme AS (CHIX:ORPHAc) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Orphazyme AS EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Orphazyme AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.orphazyme.com

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS Headlines

No Headlines